ReviewOncogene2002
Clinical impact of novel treatment strategies.
Review in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Knockdown of GINS2 inhibits proliferation and promotes apoptosis through the p53/GADD45A pathway in non-small-cell lung cancer.Bioscience reports · 2020Observational
- Targeting ZEB2 By microRNA-129 In Non-Small Cell Lung Cancer Suppresses Cell Proliferation, Invasion And Migration Via Regulating Wnt/β-Catenin Signaling Pathway And Epithelial-Mesenchymal Transition.OncoTargets and therapy · 2019Article
- Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.Frontiers in immunology · 2019Review
- PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin.Frontiers in microbiology · 2018Article
- A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer.BioMedicine · 2017Article
- Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line.Oncology letters · 2014Article
- Article
- Targeted Therapies in Lung Cancer.Surgical pathology clinics · 2010Article
- High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.The European respiratory journal · 2009Review
- Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy.Free radical research · 2009Article
- Mass spectrometry-based proteomic profiling of lung cancer.Proceedings of the American Thoracic Society · 2009Review
- Mesenchymal stem cells as vectors for lung disease.Proceedings of the American Thoracic Society · 2008Review
- Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.Cancer science · 2006Article
- The molecular basis of lung cancer: molecular abnormalities and therapeutic implications.Respiratory research · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following two decades of research on the biology of cancer and in particular of lung cancer, we have now a large number of molecular targets that can be utilized to create specific medicines against these cancers. Non-small cell lung cancer represents numerically the most important solid tumor in Western world, and is poorly affected by current therapies, where surgery represents almost the only curative therapy for about 25% of patients who are resectable at diagnosis. An abundant number of targeted therapies are being investigated in NSCLC. Among them are the metalloproteinase inhibitors, several tyrosine kinase inhibitors and several attempts of gene replacement have also been made. Promising results have so far been obtained with some of these approaches, and the outcome of large randomized studies is awaited. Small cell lung cancer (SCLC) represents about 20% of lung carcinomas, and several of the novel approaches that are being attempted for NSCLC, are also being investigated for SCLC. All these novel therapies open a new era of anticancer treatment that will likely complement the currently available therapies in the near future.
Indexed as
Identifiers
12362278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.